Lemonaid Health Now Offers Prescription ED Medication STENDRAR Through Collaboration With Petros Pharmaceuticals
Lemonaid Health Now Offers Prescription ED Medication STENDRAR Through Collaboration With Petros Pharmaceuticals
Lemonaid Health will offer customers more affordable access to fast-acting branded ED medication that works as quickly as 15 minutes prior to sexual activity
Lemonaid Health將爲客戶提供更實惠的速效品牌急診藥物，這種藥物可在性活動開始前15分鐘內起效
SUNNYVALE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Lemonaid Health, Inc., a subsidiary of 23andMe Holding Co., (Nasdaq: ME), and a leading telemedicine provider, is now offering Petros Pharmaceuticals, Inc.'s (Nasdaq: PTPI), prescription erectile dysfunction (ED) medication STENDRAR (avanafil) through its telehealth platform.
加利福尼亞州森尼韋爾，2024年5月14日（GLOBE NEWSWIRE）——23andMe Holding Co.（納斯達克股票代碼：ME）的子公司、領先的遠程醫療提供商Lemonaid Health, Inc.現在向Petros Pharmicals, Inc. 提供了 “Petros Pharmicals, Inc.”s（納斯達克股票代碼：PTPI），處方勃起功能障礙（ED）藥物 斯滕德拉R （avanafil）通過其遠程醫療平台。
Working directly with STENDRAR manufacturer Petros Pharmaceuticals, Lemonaid Health is able to offer the fast-acting ED medication at improved pricing. With one in 10 men estimated to have ED at some point in their lifetime1, Lemonaid Health clinicians are able to evaluate and prescribe patients a variety of ED medications at various price points and doses.
直接與 STENDRA 合作R 製造商 Petros Pharmicals、Lemonaid Health 能夠以更優惠的價格提供速效勃起功能障礙藥物。據估計，十分之一的男性在一生中的某個時刻患有勃起障礙1，Lemonaid Health 臨床醫生能夠以不同的價位和劑量對患者進行評估和開出各種急診藥物的處方。
"We look forward to working directly with pharmaceutical manufacturers like Petros to offer our patients improved prices and better access to brand name medications across our telemedicine offerings," said Eland Siddle, Head of Pharmacy, Lemonaid Health. "Adding STENDRAR to our ED medication offerings, gives patients more options when it comes to finding the right medication for their needs."
Lemonaid Health藥房負責人埃蘭·西德爾表示：“我們期待直接與像Petros這樣的製藥製造商合作，爲我們的患者提供更優惠的價格，讓我們的遠程醫療產品更容易獲得名牌藥物。”“添加 STENDRAR 再加上我們提供的急診藥物，在尋找滿足其需求的正確藥物方面，爲患者提供了更多選擇。”
Lemonaid Health services patients across the United States, and has treated over 200,000 ED patients to date. It provides access to medication delivery from a 50 state licensed pharmacy, which has the potential to help millions of men discreetly and legally obtain a treatment for a still significantly undertreated condition.
Lemonaid Health爲美國各地的患者提供服務，迄今爲止已經治療了超過20萬名急診患者。它爲一家擁有50個州許可的藥房提供藥物配送服務，該藥房有可能幫助數百萬男性謹慎合法地獲得治療仍嚴重不足的疾病的治療。
Important Safety Information about STENDRA (avanafil)
有關 STENDRA 的重要安全信息 （阿伐那非）
STENDRA (avanafil), originally launched by Auxilium Pharmaceuticals prior to that company's sale to Endo Pharmaceuticals, is an oral phosphodiesterase 5 (PDE5) inhibitor for the treatment of erectile dysfunction. STENDRA is not for use in women or children. It is not known if STENDRA is safe and effective in women or children under 18 years of age. A 100-mg and 200-mg tablet can be taken as early as ~15 minutes before sexual activity. STENDRA only works with sexual stimulation and should not be taken more than once a day. STENDRA can be taken with or without food; do not drink too much alcohol when taking STENDRA (for example, more than 3 glasses of wine or 3 shots of whiskey) as it can increase chances of side effects. Of people enrolled in clinical trials, 1.4%, 2.0%, and 2.0%, respectively, stopped taking STENDRA (50 mg, 100 mg, or 200 mg) due to side effects compared to 1.7% on placebo. STENDRA was designed and developed expressly for erectile dysfunction.
斯滕德拉 （avanafil）最初由Auxilium Pharmicals在出售給遠藤製藥之前推出，是一種用於治療勃起功能障礙的口服磷酸二酯酶5（PDE5）抑制劑。STENDRA 不適用於女性或兒童。目前尚不清楚STENDRA對18歲以下的女性或兒童是否安全有效。最早可以在性活動前大約 15 分鐘服用 100 毫克和 200 毫克的片劑。STENDRA 僅適用於性刺激，每天服用不應超過一次。STENDRA 可以與食物一起服用，也可以單獨服用；服用 STENDRA（例如，超過 3 杯葡萄酒或 3 杯威士忌）時不要喝太多酒精，因爲它會增加副作用的機會。在參加臨床試驗的人群中，分別有1.4％、2.0％和2.0％的人因副作用停止服用STENDRA（50 mg、100 mg或200 mg），而安慰劑的這一比例爲1.7％。STENDRA 專爲勃起功能障礙而設計和開發。
STENDRA is contraindicated with any form of organic nitrates, in patients with known hypersensitivity to any component of the tablet, and in patients who are using a guanylate cyclase stimulator.
STENDRA禁用任何形式的有機硝酸鹽，已知對片劑任何成分過敏的患者，以及使用鳥苷酸環化酶刺激劑的患者。
Patients should not use STENDRA if sexual activity is inadvisable due to cardiovascular status or any other reason. Before taking STENDRA tell your doctor if you have had any kind of heart issues including heart attack, heart failure, angina and irregular heartbeat or have elevated or low blood pressure.
如果由於心血管狀況或任何其他原因不建議進行性活動，則患者不應使用STENDRA。在服用 STENDRA 之前，請告訴醫生你是否有任何心臟問題，包括心臟病發作、心力衰竭、心絞痛和心跳不規則，或者血壓升高或過低。
Use of STENDRA with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension.
將 STENDRA 與α-受體阻滯劑、其他降壓藥或大量酒精（大於 3 個單位）一起使用可能會導致低血壓。
Patients should seek emergency treatment if an erection lasts greater than 4 hours.
如果勃起持續時間超過 4 小時，患者應尋求緊急治療。
Patients should stop STENDRA and seek medical care if a sudden loss of vision occurs in one or both eyes, which could be a sign of Non Arteritic Ischemic Optic Neuropathy (NAION). Discuss with patients the increased risk of NAION in patients with a history of NAION.
如果一隻或兩隻眼睛突然出現視力喪失，患者應停止 STENDRA 並尋求醫療護理，這可能是非動脈缺血性視神經病變 (NAION) 的徵兆。與患者討論有NAION病史的患者中NAION的風險增加。
Patients should stop taking STENDRA and seek prompt medical attention in the event of sudden decrease or loss of hearing.
如果聽力突然下降或喪失，患者應停止服用 STENDRA 並立即就醫。
STENDRA can potentiate the hypotensive effect of nitrates, alpha blockers, antihypertensives, and alcohol. CYP3A4 inhibitors (e.g., ketoconazole, ritonavir, erythromycin) increase STENDRA exposure.
STENDRA可以增強硝酸鹽、α受體阻滯劑、抗高血壓藥和酒精的降壓作用。CYP3A4 抑制劑（例如酮康唑、利托那韋、紅黴素）會增加 STENDRA 的暴露量。
Combination with Other PDE5 Inhibitors or Erectile Dysfunction Therapies is not recommended.
不建議與其他PDE5抑制劑或勃起功能障礙療法聯合使用。
The safety of STENDRA is unknown in patients with bleeding disorders and patients with active peptic ulceration.
STENDRA在出血性疾病患者和活動性消化性潰瘍患者中的安全性尚不清楚。
The use of STENDRA offers no protection against sexually transmitted diseases including HIV. Consider counseling patients on protective measures for sexually transmitted diseases.
使用STENDRA無法預防包括HIV在內的性傳播疾病。考慮就性傳播疾病的保護措施向患者提供諮詢。
The most common adverse reactions reported with use of STENDRA include headache, flushing, nasal congestion, nasopharyngitis, and back pain.
使用STENDRA時報告的最常見不良反應包括頭痛、潮紅、鼻塞、鼻咽炎和背痛。
For more information about STENDRA, call 844-458-4887. If you would like to report an adverse event or product complaint, please contact us at 844-458-4887.
有關 STENDRA 的更多信息，請致電 844-458-4887。如果您想舉報不良事件或產品投訴，請致電 844-458-4887 聯繫我們。
You are encouraged to report negative side effects of prescription drugs to the FDA by calling 1-800-FDA-1088, or at www.fda.gov/medwatch.
鼓勵你致電 1-800-FDA-1088 或 www.fda.gov/medwatch 向美國食品藥品管理局報告處方藥的負面副作用。
Please see the full Prescribing Information and Patient Information.
請查看完整內容 處方信息和患者信息。
About Lemonaid Health
Lemonaid Health, part of the 23andMe family, provides online telemedicine services in all 50 states and D.C. through its affiliated medical groups (subject to local laws). Prescriptions require completion of an independent medical consultation with a licensed healthcare provider through the Lemonaid online platform. Medications are only available if prescribed. Visit www.lemonaidhealth.com to learn more.
關於 Lemonaid Health
Lemonaid 健康是23andMe大家庭的一部分，通過其附屬醫療團體（受當地法律約束）在所有50個州和哥倫比亞特區提供在線遠程醫療服務。處方需要通過Lemonaid在線平台完成與持牌醫療保健提供者的獨立醫療諮詢。只有處方才有藥物。要了解更多信息，請訪問 www.lemonaidhealth.com。
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical fact, included or incorporated in this press release, including statements regarding 23andMe's strategy, are forward-looking statements. The words "believes," "anticipates," "estimates," "plans," "expects," "intends," "may," "could," "should," "potential," "likely," "projects," "predicts," "continue," "will," "schedule," and "would" or, in each case, their negative or other variations or comparable terminology, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are predictions based on 23andMe's current expectations and projections about future events and various assumptions. 23andMe cannot guarantee that it will actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements and you should not place undue reliance on 23andMe's forward-looking statements. These forward-looking statements involve a number of risks, uncertainties (many of which are beyond the control of 23andMe), or other assumptions that may cause actual results or performance to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's filings with the Securities and Exchange Commission, including under Item 1A, "Risk Factors" in the Company's most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission, and as revised and updated by our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The statements made herein are made as of the date of this press release and, except as may be required by law, 23andMe undertakes no obligation to update them, whether as a result of new information, developments, or otherwise.
前瞻性陳述
本新聞稿包含經修訂的1933年《證券法》第27A條和經修訂的1934年《證券交易法》第21E條所指的前瞻性陳述。除歷史事實陳述外，本新聞稿中包含或納入的所有陳述，包括有關23andMe戰略的陳述，均爲前瞻性陳述。“相信”、“預期”、“估計”、“計劃”、“預期”、“打算”、“可能”、“應該”、“潛在”、“可能”、“項目”、“預測”、“繼續”、“將”、“計劃” 和 “將”，或者，在每種情況下，它們的負面或其他變體或可比術語旨在識別前瞻性陳述，儘管不是所有前瞻性陳述都包含這些識別詞。這些前瞻性陳述是基於23andMe當前對未來事件的預期和預測以及各種假設的預測。23andMe無法保證它會真正實現其前瞻性陳述中披露的計劃、意圖或預期，您不應過分依賴23andMe的前瞻性陳述。這些前瞻性陳述涉及許多風險、不確定性（其中許多是23andMe無法控制的）或其他假設，這些假設可能導致實際業績或業績與這些前瞻性陳述所表達或暗示的業績存在重大差異。此處包含的前瞻性陳述通常還受公司向美國證券交易委員會提交的文件中不時描述的其他風險和不確定性的影響，包括1A項下的公司向美國證券交易委員會提交的最新10-K表年度報告中的 “風險因素”，以及我們的10-Q表季度報告和8-K表最新報告的修訂和更新。此處發表的聲明是截至本新聞稿發佈之日發表的，除非法律要求，否則23andMe沒有義務對其進行更新，無論是由於新信息、事態發展還是其他原因。
Contacts
Investor Relations Contact: investors@23andMe.com
Media Contact: press@23andMe.com
聯繫人
投資者關係聯繫人： investors@23andMe.com
媒體聯繫人： press@23andMe.com
1 Cleveland Clinic, 2019
1 克利夫蘭診所，2019
譯文內容由第三人軟體翻譯。